Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Four ultrasound devices added to third-party review program via FDA final guidance.

This article was originally published in The Gray Sheet

Executive Summary

FDA FINAL 510(k) GUIDANCE ON ULTRASOUND SYSTEMS AND TRANSDUCERS brings to 27 the number of Class II devices eligible for outside scrutiny under the agency's third-party 510(k) review pilot. Although the guidance applies to all ultrasound equipment, the agency's Sept. 30 release of the final version permits FDA to add four specific Class II ultrasound devices to the third-party review program: nonfetal ultrasonic monitors, ultrasonic pulsed doppler imaging systems, ultrasonic pulsed echo imaging systems, and diagnostic ultrasonic transducers.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel